Motion Sickness Clinical Trial
Official title:
Evaluation and Countermeasures of Motion Sickness by Virtual Reality Desensitization Protocol
Evaluation of a virtual reality desensitization protocol on subjects with severe motion sickness and study of the role of the emotional component on the effectiveness of the therapy.
Motion sickness is a well-known syndrome, particularly at risk in children, with a maximum around the age of 12. All people are sensitive to motion sickness in childhood, probably related to the maturation of certain cognitive functions of a spatial nature, namely the perception of oneself and one's movements in one's environment. These symptoms regress with age for a part of the population but a large number of people will remain sensitive to certain conditions of displacement and generate symptoms that can be extremely disabling and handicapping in everyday life, particularly for professional activities. For example, some people can no longer use their car, some can no longer take the boat for professional activities in restrictive and/or extreme environments (sailors, scientists, workers, etc.). Behavioral, respiratory or medicinal therapies remain partially effective due to the lack of sufficient knowledge on the physiopathology of this syndrome classified in the field of sensory disorders. Very recently, techniques of sensory desensitization by visual stimulation have appeared, either optokinetic or in virtual reality mimicking the environment that causes this syndrome. This therapeutic approach seems to give empirically good results but only one study has shown it with optokinetic stimulation but it is to be evaluated for virtual reality. The main objective of the study is therefore to evaluate the effectiveness of a sensory conflict protocol generated in virtual reality to reduce the severity of motion sickness. Each subject being his own control. An observational study was then designed to quantify the effectiveness of this technique carried out in a current way by the physiotherapists in the form of questionnaires supplemented by a posturographic evaluation of the sensory profile of the subjects. If the effectiveness is proven, this desensitization protocol could be optimized and more widely distributed. Furthermore, the analysis of the visuo-dependence variable (from the sensory profile) will indicate whether the use of a visual stimulus by virtual reality alone is sufficient or should be combined or compared with desensitization of other sensory modalities. The use of galvanic vestibular stimulation for the rehabilitation of vestibular pathologies or training programs based on the resolution of sensory conflicts could be envisaged in the future. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Recruiting |
NCT06128707 -
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
|
||
Completed |
NCT05611814 -
Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms
|
N/A | |
Recruiting |
NCT06106256 -
Three-Axis Wearable Adaptive Vestibular Stimulator
|
N/A | |
Completed |
NCT02839135 -
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
|
Phase 1 | |
Completed |
NCT04420949 -
Sensory Training for Visual Motion Sickness
|
N/A | |
Completed |
NCT04184115 -
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
|
Phase 3 | |
Completed |
NCT03988530 -
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
|
Phase 3 | |
Terminated |
NCT04219982 -
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
|
Phase 2/Phase 3 | |
Terminated |
NCT02155309 -
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
|
Phase 2/Phase 3 | |
Completed |
NCT04947423 -
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
|
Phase 3 | |
Recruiting |
NCT05903924 -
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
|
Phase 3 | |
Recruiting |
NCT04999449 -
Nebulizer Delivery of Intranasal Scopolamine
|
Phase 1 | |
Recruiting |
NCT05886660 -
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
|
Phase 2 | |
Completed |
NCT03755596 -
Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness
|
Phase 4 | |
Recruiting |
NCT06138613 -
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
|
Phase 3 | |
Completed |
NCT04327661 -
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
|
Phase 3 | |
Completed |
NCT06232785 -
Gynecologic Endoscopic Surgery of Female Motion Sickness Patients
|
Phase 4 | |
Completed |
NCT06056622 -
Motion Sickness Rehabilitation for Virtual Reality
|
N/A | |
Withdrawn |
NCT04331561 -
Sensory Training for Orientation and Balance
|
N/A |